Diagnosis and Complication Risk Assessment of Pancreatic Diabetes within Normal Value Ranges of Leuc
- 总结
- This patent can use for daily complication risk Assessment of all diabetic patients and save lifes, suffering from the diabetic complications at all around the world. it is more important method than Hemoglobin A1c. Because all diabetic complications can monitorizing using one marker (procalcitonin) in 24 hours period. New technology of insulin pump system or traditional diabetes mellitus therapy need this invention for proper diabetic complication (retinopathy, nephropathy,neuropathy) treatment
- 详细技术说明
- This method use rapid or Automatic test device for procalcitonin blood levels
- 合作类型
- License agreement
- 附加资料
- Inventor: Chonge Chen | Cleph. Sturt. Keklam | chuxian Wu
Priority Number: CN100572554C
IPC Current: C12Q000168
Assignee Applicant: The Chinese University of Hong Kong
Title: Risk estimution for diabetic to suffer from diabetic renopathy or blood-lipid imbalance | Evaluation diabetes patients suffer from diabetic nephropathy, or dyslipidemia disorder risk of
Usefulness: Risk estimution for diabetic to suffer from diabetic renopathy or blood-lipid imbalance | Evaluation diabetes patients suffer from diabetic nephropathy, or dyslipidemia disorder risk of
Novelty: Risk estimation for diabetic to suffer from diabetic renopathy or blood-lipid imbalance
- 主要类别
- 诊断/治疗
- 细分类别
- 其他疾病
- 申请号码
- EP20120154587
- 覆盖范围
- EPO designated contracting states
- 专利信息
- Status: Patent Application
- 其他
- Price: negotiable
- 国家/地区
- 土耳其
欲了解更多信息,请点击 这里
